Directors' Dealings

Issue of Equity

London and New York, 13 May 2009 - Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, today announces that it is to issue 207,189 ordinary shares pursuant to interest owed to shareholders, including the Chief Executive Officer, in respect of the Convertible Promissory Notes.

Richard Morgan, Chief Executive Officer of Amphion, received 151,233 ordinary shares in respect of accrued interest, at 7 per cent per annum, on his Convertible Promissory Notes.  Accordingly, Mr Morgan has a beneficial interest in 23,727,499 ordinary shares, representing 18.02% of the Company's enlarged issued ordinary share capital. 

Accordingly, application has been made for the 207,189 new ordinary shares, to be admitted to trading on AIM and it is expected that admission will take place on 21 May 2009.

The new ordinary shares will rank pari passu with the existing shares of the Company. Following this allotment, the total issued share capital of the Company will increase to 131,682,060 ordinary shares.

For further information please contact 

Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 (212) 210 6224

Cardew Group
Tim Robertson/ Jamie Milton/ Matthew Law
+44 20 7930 0777

Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley
+44 20 7149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in ten Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion.    Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com